Kenneth L. Clark
Stevenage, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.
Journal: Annals of the rheumatic diseases
Published: February 16, 2024
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome.
Journal: JCI insight
Published: June 24, 2022
A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
Published: April 27, 2019
The affinity, intrinsic activity and selectivity of a structurally novel EP2 receptor agonist at human prostanoid receptors.
Journal: British journal of pharmacology
Published: December 16, 2017
Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis.
Journal: Bioorganic & medicinal chemistry letters
Published: August 22, 2017
Design of Phthalazinone Amide Histamine H1 Receptor Antagonists for Use in Rhinitis.
Journal: ACS medicinal chemistry letters
Published: April 05, 2017
Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs.
Journal: Molecular therapy. Nucleic acids
Published: October 12, 2016
In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization.
Journal: Nucleic acids research
Published: December 22, 2014
From virtual to clinical: The discovery of PGN-1531, a novel antagonist of the prostanoid EP4 receptor.
Journal: Bioorganic & medicinal chemistry letters
Published: January 08, 2014
Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis.
Journal: Molecular therapy. Nucleic acids
Published: January 17, 2013
Pharmacological characterization of GSK1004723, a novel, long-acting antagonist at histamine H(1) and H(3) receptors.
Journal: British journal of pharmacology
Published: October 26, 2011
Showing 1-11 of 11
Last Updated: 09/26/2026